Latest Regulatory Engagement News

Page 6 of 18
Torque Metals is advancing its Paris Gold Camp project in Western Australia, moving from exploration to development readiness with a 250,000-ounce gold resource and an aggressive drilling program.
Maxwell Dee
Maxwell Dee
29 Jan 2026
Finder Energy Holdings has completed the acquisition of the Petrojarl I FPSO, a critical step that de-risks the KTJ Project and accelerates its path to a Final Investment Decision expected by mid-2026. The company also secured A$25 million in funding and achieved a significant resource upgrade.
Maxwell Dee
Maxwell Dee
28 Jan 2026
Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.
Ada Torres
Ada Torres
23 Jan 2026
NH3 Clean Energy has marked significant progress in its WAH2 clean ammonia project, securing major offtake agreements and government facilitation support alongside a $4 million institutional funding round.
Maxwell Dee
Maxwell Dee
22 Jan 2026
Entropy Neurodynamics reports encouraging early clinical results from the first patient treated with TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, showing improvements across multiple symptom areas.
Ada Torres
Ada Torres
22 Jan 2026
Insignia Financial’s Funds Under Management and Administration edged up to $342 billion, driven by strong inflows into its Wrap platform and multi-asset solutions, while Master Trust funds faced ongoing outflows amid product transitions.
Claire Turing
Claire Turing
22 Jan 2026
NobleOak Life Limited has increased its stamp duty provision to $6.5 million following a dispute with the Victorian State Revenue Office over exemption eligibility, prompting pricing changes and ongoing regulatory engagement.
Claire Turing
Claire Turing
16 Jan 2026
NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.
Ada Torres
Ada Torres
13 Jan 2026
AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.
Ada Torres
Ada Torres
13 Jan 2026
Island Pharmaceuticals reports ongoing FDA review of its antiviral Galidesivir, with no adverse feedback received as the regulator takes extra time to finalise guidance.
Victor Sage
Victor Sage
5 Jan 2026
Neurizon Therapeutics has progressed its ALS treatment NUZ-001 into critical clinical trial phases, even as the FDA declines its Fast Track Designation request pending more data.
Ada Torres
Ada Torres
2 Jan 2026
Western Gold Resources has approved the Decision to Mine for its Gold Duke Project, marking a key shift from exploration to production with first gold targeted in early 2026.
Maxwell Dee
Maxwell Dee
24 Dec 2025